US Court Rules in Favor of Sanofi and Regeneron in Praluent Patent Case

September 3, 2019

A District Court for the US District of Delaware has ruled in favor of Sanofi and Regeneron in the patent case targeting proprotein convertase subtilisin/kexin type 9 (PCSK9).

A District Court for the US District of Delaware has ruled in favor of Sanofi and Regeneron in the patent case targeting proprotein convertase subtilisin/kexin type 9 (PCSK9), it was revealed in an Aug. 29, 2019 press statement.

The ruling was made due to a “lack of enablement” it was specified in the press release and has meant that sections of an earlier jury verdict have been overturned. As a result of this latest court ruling, Sanofi and Regeneron have invalidated all five patent claims made against them by Amgen.

“It has been our longstanding belief that all of Amgen’s asserted US PCSK9 patent claims are invalid, and we are pleased today’s decision reaffirms this,” said Karen Linehan, executive vice-president and general counsel, Sanofi, in the press release. 

“Today’s decision by the US District Court for the District of Delaware validates our position that Amgen’s patents are overly broad and invalid,” added Joseph LaRosa, executive vice-president, general counsel and secretary, Regeneron. “Praluent was developed using Regeneron’s proprietary science and technology, and the judge has confirmed our position by issuing this ruling.”

Source: Sanofi